Jeffrey A Engelman Selected Research

Jeffrey A Engelman Research Topics

Disease

124	Neoplasms (Cancer) 11/2021 - 05/2005
64	Lung Neoplasms (Lung Cancer) 01/2021 - 08/2005
34	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2019 - 03/2005
12	Breast Neoplasms (Breast Cancer) 01/2020 - 12/2005
7	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 11/2010
7	Adenocarcinoma of Lung 01/2017 - 10/2006
5	Melanoma (Melanoma, Malignant) 01/2019 - 03/2012
5	Carcinoma (Carcinomatosis) 01/2017 - 10/2006
4	Disease Progression 10/2016 - 10/2012
4	Carcinogenesis 04/2014 - 09/2010
3	Brain Neoplasms (Brain Tumor) 01/2017 - 11/2012
3	Oncogene Addiction 02/2015 - 09/2011
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2019 - 10/2018
2	Sarcoma (Soft Tissue Sarcoma) 01/2017 - 12/2011
2	Neoplasm Metastasis (Metastasis) 11/2016 - 02/2016
2	Adenocarcinoma 09/2015 - 05/2012
2	Hypersensitivity (Allergy) 08/2013 - 03/2005
2	Lymphoma (Lymphomas) 05/2012 - 05/2011
2	Insulin Resistance 08/2005 - 03/2005
1	Ovarian Neoplasms (Ovarian Cancer) 10/2020
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2019
1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2019

Drug/Important Bio-Agent (IBA)

36	ErbB Receptors (EGF Receptor)IBA 01/2019 - 03/2005
28	Phosphotransferases (Kinase)IBA 01/2021 - 07/2005
28	Tyrosine Kinase InhibitorsIBA 01/2019 - 05/2005
27	Pharmaceutical PreparationsIBA 01/2021 - 06/2008
21	CrizotinibIBA 10/2016 - 10/2010
19	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021 - 12/2008
16	Anaplastic Lymphoma KinaseIBA 01/2018 - 07/2008
16	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2016 - 05/2005
15	Gefitinib (Iressa)FDA Link 12/2011 - 03/2005
12	Biomarkers (Surrogate Marker)IBA 10/2020 - 07/2010
11	Phosphatidylinositols (Phosphatidylinositol)IBA 07/2014 - 03/2005
8	Proteins (Proteins, Gene)FDA Link 01/2021 - 11/2009
6	tyrosine receptor (receptor, tyrosine)IBA 01/2020 - 02/2011
6	ceritinibIBA 10/2016 - 01/2014
5	Mitogen-Activated Protein KinasesIBA 01/2017 - 11/2010
5	LigandsIBA 01/2017 - 08/2007
5	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 11/2013 - 08/2005
4	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021 - 03/2012
4	Mechanistic Target of Rapamycin Complex 1IBA 01/2019 - 07/2013
4	Cetuximab (Erbitux)FDA Link 07/2015 - 08/2005
4	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2015 - 02/2010
4	Small Interfering RNA (siRNA)IBA 01/2013 - 08/2008
4	AZD 6244IBA 03/2012 - 12/2008
4	Insulin (Novolin)FDA Link 12/2011 - 03/2005
3	nazartinibIBA 01/2021 - 03/2016
3	SHP099IBA 01/2020 - 01/2019
3	navitoclaxIBA 01/2019 - 03/2015
3	lorlatinibIBA 01/2018 - 01/2016
3	RNA (Ribonucleic Acid)IBA 12/2017 - 09/2011
3	alectinibIBA 11/2016 - 11/2014
3	Trastuzumab (Herceptin)FDA Link 02/2016 - 08/2007
3	Proto-Oncogene Proteins c-metIBA 01/2016 - 03/2010
3	AlpelisibIBA 01/2015 - 07/2013
3	TOR Serine-Threonine KinasesIBA 03/2014 - 12/2008
3	Protein Kinases (Protein Kinase)IBA 12/2013 - 11/2010
3	MitogensIBA 07/2013 - 06/2010
2	Tyrosine (L-Tyrosine)FDA Link 01/2021 - 07/2011
2	Protein Isoforms (Isoforms)IBA 01/2021 - 01/2015
2	CytokinesIBA 01/2021 - 04/2014
2	Protein Tyrosine PhosphatasesIBA 12/2019 - 02/2016
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2019 - 03/2012
2	trametinibIBA 01/2019 - 01/2016
2	Type 1 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 1)IBA 01/2019 - 12/2012
2	Circulating Tumor DNAIBA 01/2018 - 03/2016
2	Immune Checkpoint InhibitorsIBA 01/2018 - 09/2016
2	DNA (Deoxyribonucleic Acid)IBA 12/2017 - 05/2008
2	Phenobarbital (Luminal)FDA Link 01/2017 - 01/2015
2	B7-H1 AntigenIBA 01/2017 - 02/2016
2	Transcription Factors (Transcription Factor)IBA 11/2016 - 06/2010
2	rociletinibIBA 04/2016 - 07/2015
2	human ERBB2 proteinIBA 02/2016 - 03/2010
2	NucleotidesIBA 07/2015 - 08/2013
2	Biological ProductsIBA 07/2015 - 06/2008
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 02/2015 - 12/2005
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2015 - 11/2012
2	NVP-TAE684IBA 03/2014 - 05/2011
2	Protein Kinase CIBA 12/2013 - 12/2011
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 09/2013 - 06/2010
2	5- ((2,6- dichlorobenzyl)sulfonyl)- 3- ((3,5- dimethyl- 4- ((2- (pyrrolidin- 1- ylmethyl)pyrrolidin- 1- yl)carbonyl)- 1H- pyrrol- 2- yl)methylene)- 1,3- dihydro- 2H- indol- 2- oneIBA 05/2013 - 02/2011
2	Epidermal Growth Factor (EGF)IBA 11/2012 - 05/2008
2	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 05/2012 - 05/2011
2	Monoclonal AntibodiesIBA 12/2011 - 07/2008
2	Neuregulin-1 (Neuregulin 1)IBA 09/2011 - 03/2010
2	MAP Kinase Kinase Kinases (MAP Kinase Kinase Kinase)IBA 04/2011 - 06/2010
2	dactolisibIBA 11/2009 - 12/2008
1	Chemotactic FactorsIBA 01/2021
1	naporafenibIBA 01/2021
1	Cell-Free Nucleic AcidsIBA 01/2021
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2021
1	ribociclibIBA 01/2021
1	InterferonsIBA 12/2020
1	Estrogen Receptor Modulators (Antiestrogen)IBA 01/2020
1	MTOR InhibitorsIBA 01/2019
1	Surface Antigens (Surface Antigen)IBA 10/2018

Therapy/Procedure

74	Therapeutics 11/2021 - 03/2005
7	Drug Therapy (Chemotherapy) 10/2020 - 05/2008
5	Aftercare (After-Treatment) 01/2018 - 07/2013
3	Immunotherapy 01/2021 - 01/2017